
The planned study will assess the safety, efficacy, and optimal dosing of the investigational therapy in approximately 150 patients with DED.

The planned study will assess the safety, efficacy, and optimal dosing of the investigational therapy in approximately 150 patients with DED.

Examining the physiologic limits and patient selection for warm compress therapy in meibomian gland dysfunction can help identify when its usage may be ineffective.

Aleman-Moheeputh, OD, details the difficulties undocumented immigrants often face in the search for accessible care.

Carolyn Majcher, OD, FAAO, discusses the pivotal and necessary role OCT plays in managing and diagnosing AMD.

Andrew Bruce LDO, ABOM, NCLEM, FCLSA, and Mark Schaeffer, OD, FAAO, weigh in on how opticians and optometrists can work together to find ideal contact lens candidates at Vision Expo 2026 in Orlando, Florida.

Glenda Aleman-Moheepith, OD, states that using technology for translation efforts can make a world of a difference in putting them at ease in your chair.

Sheila Morrison, OD, MS, explores the clinical intersection of dry eye disease and myopia control in pediatric patients—and why that intersection matters more than many practitioners realize.

Henry, MS, OD, presented a talk on how AI can help alleviate burnout for ODs during Vision Expo 2026 in Orlando, Florida.

A handful of ECPs weigh in on what ODs and MDs alike should know to spread awareness of the disease state.

According to the company, the lens is the first and only FDA-approved EDOF IOL in the US without a warning regarding loss of contrast sensitivity.

The annual See Tomorrow survey conducted by the Contact Lens Institute and the United Opticians Association has highlighted a substantial portion of both opticians and patients interested in further education.

Jeffry D. Gerson, OD, FAAO, shares how early exposure to retinal disease, mentorship, and hands-on OCT experience shaped his career and inspired a commitment to education and collaboration with ophthalmology.

John Womack, OD, details a poster on real-world data on a kalifilcon A daily disposable silicone hydrogel toric contact lens he presented at SECO 2026.

For many patients with mild to moderate allergic conjunctivitis, OTC ophthalmic medications can provide effective relief.

Nate Lighthizer, OD, FAAO, offers practical advice for clinicians adopting YAG capsulotomy.

In the urge to intervene early, optometrists are turning to low-dose atropine as a tool to combat myopia progression.

The study highlights the broader impact of OR on patients’ quality of life.

Nathan Lighthizer, OD, FAAO, presented on laser trabeculoplasty for glaucoma management at this year's conference.

Amniotic membrane therapy has been used in refractory cases to protect the ocular surface, modulate inflammation and fibrosis, and promote epithelial healing.

Mile Brujic, OD, FAAO, presented data from a study in February 2026 that examined real-world experience with lifitegrast across 12 offices—6 ophthalmology and 6 optometry practices.

Inder Paul Singh, MD, emphasized that patient compliance is a real and significant challenge in glaucoma care.

The review notes aesthetic considerations are increasingly important as social media and video conferencing spotlight facial appearance.

The ADVISE trial has demonstrated adalimumab’s superior management of intermediate uveitis, posterior uveitis, or panuveitis requiring immunosuppression.

Larissa Camejo, MD, emphasized that decisions are never “black and white” and must be individualized based on the specific patient.

Researchers examined 3 primary associations: the risk of developing uveitis following an IMID diagnosis, the odds of having a prior IMID among uveitis patients, and the risk of developing an IMID after a uveitis diagnosis.

Learn the latest on legislative updates from Arkansas, Texas, South Carolina, and Pennsylvania.

The company said the expansions support its goal of making evidence-based myopia management accessible to eye care professionals and children worldwide.

The clinical study will evaluate a noninvasive corneal strengthening procedure designed to reshape the cornea and correct refractive errors in-office without tissue removal.

A recent nonrandomized trial has demonstrated toric IOLs’ efficacy in providing long-term visual outcomes, reducing amblyopia compared to non-toric lenses.